Surrendered on reissue Nov 28, 2023 · Low confidence
20-year base term ends Jul 6, 2030
Surrendered on reissue Nov 28, 2023 · its term and maintenance fees continue in US RE49,736.
Held by Jazz Pharmaceuticals II SAS
Filed Aug 5, 2015 as application 14/819,305 · Granted Mar 20, 2018
Base term, 20 years from filing
Today
Surrendered Nov 28, 2023
2010
2030
Clock starts
Jul 6, 2010
Jul 6, 2010
No longer in force
Nov 28, 2023
Nov 28, 2023
Granted
Mar 20, 2018
Mar 20, 2018
Term would have run to
Jul 6, 2030
Jul 6, 2030
base term
after the term ends
fee events
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
1 of 3
Maintenance fees paid
Fees paid on this patent before its reissue. Those after fall due on the reissue, which carries the term on.
7
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. Confidence: Low. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jul 6, 2010, when application PCT/EP2010/059599, the earliest non-provisional in its chain, was filed (this one was filed Aug 5, 2015); a parent in its chain could not be resolved (the next row) | Jul 6, 2030 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | No fee event states this; the fee state is read from the payments the fee record holds; the fee record shows no payment for this window, and USPTO's status still reads "Patented Case" | no change | Low confidence |
| Reissue | US RE49,736 issued Nov 28, 2023, and this patent's term continues in it (35 U.S.C. 251, 252) | surrendered Nov 28, 2023 | High confidence |
| Surrendered on reissue | The steps above, in order | Nov 28, 2023 | Low confidence |
Partial family
| Application PCT/EP2010/059599 | PCT application no patent term | no patent term |
| Application 13/382,276 | Abandoned not computed | not computed |
| US 9,920,311 | this patent Nov 2023 | Nov 2023 |
| Application 15/886,216 | Abandoned not computed | not computed |
| US RE49,736 | In force Jul 2030 | Jul 2030 |
| US 11,046,946 | In force no later than Jul 2030 | no later than Jul 2030 |
| US 12,441,992 | In force Jul 2030 | Jul 2030 |
Partial: 1 of the 7 has no file history here, so its row comes from the patent's own record or names the application alone. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Feb 1, 2018 Reel 44801, frame 637 | Abribat, Thierry | Alize Pharma II SAS | Assignment of Assignor's Interest |
| Feb 1, 2018 Reel 45869, frame 451 | Alize Pharma II | Jazz Pharmaceuticals II SAS | Change of Name |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
Citations
43
later US patents cite this one
That is top 10% of utility patents granted in 2018 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.